Target (TGT) closed the most recent trading day at $150.40, moving -1.18% from the previous trading session.
Altimmune, Inc.'s weight loss drug, pemvidutide, shows significant superiority in lean mass retention and liver fat reduction, making it a potential takeover target. High short interest in Altimmune stock could trigger a short-covering rally if reports of takeover talks emerge. Pemvidutide's superior lean mass retention could enable it to capture market share from Novo Nordisk's Wegovy and Eli Lilly's tirzepatide.
Wells Fargo issued a rare price target cut for the Mag 7 company, citing caution on Google search growth amid regulatory headlines. However, Caroline Woods notes bullishness from other analysts which paint a different picture of Alphabet (GOOGL).
APO outlines its financial targets for 2029, indicating a strong growth trajectory. Its shares rise 5.7% following the news.
Target (TGT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Meta stock received another price target hike early Monday, as analysts review last week's AI, metaverse event.
When interest rates are high, income investors may gravitate toward risk-free products and away from dividend stocks. Target's results have improved, but it still has more work to do.
Target (TGT) closed at $155.98 in the latest trading session, marking a +0.59% move from the prior day.
Amazon's video ad revenue for the 2024-25 upfront period has exceeded the tech giant's internal target of $1.8 billion, a person familiar with the financials has confirmed to Deadline.
Despite challenges, Target's ability to attract and retain customers through its value-driven approach and loyalty programs signals resilience.
VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / Relevant Gold Corp. (TSXV:RGC)(OTCQB:RGCCF) (the "Company" or "Relevant Gold") announces final results from its 2024 geologic mapping and rock chip sampling program at its 100% owned Bradley Peak Gold Camp in central Wyoming. Results demonstrate widespread high-grade gold and copper mineralization, which refine three previously identified, and reveal three new, high-potential exploration targets (see below, Table 1).
Last week, Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.